文献速递银屑病与炎症性皮肤病湿疹皮炎与荨麻疹

托法替布治疗SAPHO综合征指甲病变与掌跖脓疱病

Tofacitinib for the Treatment of Nail Lesions and Palmoplantar Pustulosis in Synovitis, Acne, Pustulosis, Hyperostosis, and Osteitis Syndrome.
PubMed 文献 · JAMA Dermatol · 2021-01-01

这项开放标签单臂前瞻性试点研究纳入13例伴指甲病变和活动性掌跖脓疱病的SAPHO综合征患者,口服托法替布5 mg每日两次治疗12周。结果显示指甲银屑病严重指数中位改善-67%,掌跖银屑病面积严重指数中位改善-71%,生活质量显著改善,未观察到严重不良事件。

要点

  • 托法替布5 mg每日两次治疗12周可显著改善SAPHO综合征患者的指甲病变和掌跖脓疱病。
  • 治疗12周时指甲银屑病严重指数中位下降67%,掌跖银屑病面积严重指数中位下降71%。
  • 研究为开放标签单臂试点研究,样本量小,长期疗效和安全性需进一步随访研究。

核心结论

  • 托法替布可使SAPHO综合征患者的指甲病变和掌跖银屑病获得显著缓解,并改善生活质量。
  • 需进一步随访研究评估托法替布治疗SAPHO综合征指甲受累的长期疗效和安全性。

研究设计与样本

  • 开放标签、单臂、前瞻性试点研究,纳入13例来自北京协和医院的SAPHO综合征伴指甲病变和活动性掌跖脓疱病患者。
  • 参与者接受托法替布5 mg每日两次治疗12周,随访于2020年3月完成。
  • 主要终点为第12周指甲银屑病严重指数(NAPSI)评分较基线的变化百分比。

主要发现

  • 13例女性亚洲患者(平均年龄39.7岁,SD 12.3)均完成研究。
  • 第12周NAPSI评分中位变化-67%(IQR -56%至-77%),P < .001。
  • 第12周掌跖银屑病面积严重指数(PPPASI)评分中位变化-71%(IQR -58%至-78%),P < .001。
  • 第12周皮肤病生活质量指数(DLQI)评分中位变化-12(IQR -8.5至-15),P < .001。
  • 第8周整体骨关节疼痛视觉模拟量表(VAS)评分中位变化-4(IQR 0至-5),P = .02;第12周无统计学显著性。

临床怎么用

  • 对于SAPHO综合征伴指甲病变和掌跖脓疱病的患者,托法替布5 mg每日两次治疗12周可能作为治疗选择。
  • 治疗期间需监测指甲病变、掌跖脓疱病、生活质量和炎症标志物的变化。

局限性

  • 开放标签、单臂设计,缺乏对照,存在偏倚风险。
  • 样本量小(13例),且均为女性亚洲患者,结果外推受限。
  • 随访时间短(12周),长期疗效和安全性未评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Nail involvement is common in synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome, which has a strong association with quality of life in patients with SAPHO. Tofacitinib is an oral Janus kinase inhibitor that has been previously shown to be effective for nail psoriasis. OBJECTIVE: To assess the efficacy and safety of tofacitinib for the treatment of nail involvement in SAPHO syndrome. INTERVENTIONS: Participants received tofacitinib, 5 mg, twice daily, for 12 weeks. DESIGN, SETTING, AND PARTICIPANTS: This open-label, single-arm, prospective pilot study included 13 patients with SAPHO syndrome accompanied by nail lesions and active palmoplantar pustulosis who were recruited from Peking Union Medical College Hospital from September 2019 to December 2019. Follow-up was completed in March 2020. Analysis began March 2020. MAIN OUTCOMES AND MEASURES: The primary end point was the percentage of the change from baseline in Nail Psoriasis Severity Index scores at week 12. Secondary end points included the percentage of the change from baseline in Palmoplantar Psoriasis Area and Severity Index scores, change from baseline in Visual Analogue Scale scores in global osteoarticular pain, Dermatology Life Quality Index scores, and inflammatory markers. Adverse events were recorded throughout the study. RESULTS: Thirteen female Asian patients (means [SD] age, 39.7 [12.3] years) were included, all of whom completed the study. At week 12, significant improvements were observed in Nail Psoriasis Severity Index scores (median, -67% [interquartile range (IQR), -56% to -77%]; P < .001) and Palmoplantar Psoriasis Area and Severity Index scores (median, -71% [IQR, -58% to -78%]; P < .001). Significant improvement was also noted in Dermatology Life Quality Index scores (median, -12 [IQR, -8.5 to -15]; P < .001) at week 12. A significant decrease in Visual Analogue Scale scores in global osteoarticular pain was observed at week 8 (median, -4 [IQR, 0 to -5]; P = .02) but was not significant at week 12. Inflammatory marker levels were decreased, as indicated by erythrocyte sedimentation rate (median, -8 mm/h [IQR, -4 mm/h to -11 mm/h]; P < .001) and high-sensitivity C-reactive protein levels (median, -1.6 [IQR, -0.3 to -4.1]; P = .01). No severe adverse events were observed. CONCLUSIONS AND RELEVANCE: In this pilot study, tofacitinib yielded significant remission of nail lesions and palmoplantar psoriasis accompanied by an improvement in quality of life in patients with SAPHO syndrome. Additional follow-up studies to evaluate the long-term efficacy and safety of tofacitinib for nail involvement in SAPHO syndrome are warranted. TRIAL REGISTRATION: Chinese Clinical Trial Registry number: ChiCTR1900025941.

来源:JAMA Dermatol,查看原文。版权归原作者所有。

引用

  1. Li C, Li Z, Cao Y, et al. Tofacitinib for the Treatment of Nail Lesions and Palmoplantar Pustulosis in Synovitis, Acne, Pustulosis, Hyperostosis, and Osteitis Syndrome. JAMA Dermatol. 2021. PMID: 32997094. doi:10.1001/jamadermatol.2020.3095

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。